SCHEMBL20356708

SCHEMBL20356708

Cc1nc(C(=O)O)nc(OCc2ccccc2F)c1Cc1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ PTGER1 P34995 2/20 0.41
▸ CLCN2 P51788 1/20 0.39
▸ NR4A2 P43354 2/20 0.39
▸ ENPP1 P22413 1/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ MAOB P27338 1/20 0.39
▸ TP53 P04637 3/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ LPAR1 Q92633 1/20 0.37
▸ LPAR5 Q9H1C0 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MAPK8 P45983 1/20 0.37
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21526008 0.91 PTGER1 (0.43) ALDH1A1HPGDHSD17B10SMN1; SMN2PTGER1
SCHEMBL20356576 0.88 SMN1; SMN2 (0.44) ALDH1A1HPGDSMN1; SMN2PTGER1NR4A2
SCHEMBL20356707 0.88 SMN1; SMN2 (0.41) ALDH1A1KDM4EHPGDSMN1; SMN2PTGER1
SCHEMBL21525997 0.85 SMN1; SMN2 (0.46) ALDH1A1HPGDHSD17B10SMN1; SMN2NR4A2
SCHEMBL20356709 0.85 NR4A2 (0.42) ALDH1A1KDM4EHPGDSMN1; SMN2NR4A2
Hydrochloric Acid SCHEMBL21526118 0.84 SMN1; SMN2 (0.45) ALDH1A1HPGDHSD17B10SMN1; SMN2NR4A2
SCHEMBL21526040 0.84 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2PTGER1NR4A2ENPP1
SCHEMBL20356567 0.84 SMN1; SMN2 (0.41) ALDH1A1HPGDSMN1; SMN2PTGER1NR4A2
SCHEMBL20356657 0.84 SMN1; SMN2 (0.44) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL21525996 0.83 SMN1; SMN2 (0.48) ALDH1A1HPGDHSD17B10SMN1; SMN2ENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564216-B1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-27 — — EP disclosed
EP-3564216-B1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-27 — — EP disclosed
US-11034659-B2 Pyrimidine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-15 — — US disclosed
US-20200172494-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-06-04 — — US disclosed
EP-3564216-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-11-06 — — EP disclosed
EP-3564216-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-11-06 — — EP disclosed
WO-2018124000-A1 PYRIMIDINE DERIVATIVE 第一三共株式会社 2018-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11034659-B2 Pyrimidine derivative GPR39, CFTR, TMEM109 ALDH1A1 3457/4885KDM4E 4694/4885HPGD 2237/4885
US-20200172494-A1 PYRIMIDINE DERIVATIVE GPR39, CFTR, TMEM109 ALDH1A1 3457/4885KDM4E 4694/4885HPGD 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback